Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma

Overview

The purpose of this is to test the safety and effectiveness of an investigational chemotherapy agent in patients with persistent or recurrent endometrial cancer.

Full Title of Study: “A Phase 2 Study of ET-743 as Second-Line Therapy in Subjects With Persistent or Recurrent Endometrial Carcinoma”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)

Detailed Description

Patients will be enrolled in the study after all study-specific entry criteria are met and informed consent is obtained. Patients will be required to attend regular clinic visits to receive study medication and have their status monitored. They will also be required to have radiologic tumor assessments performed at multiple times throughout the study. A detailed explanation can be provided by the Investigator conducting this study. Trabectedin 1.3 mg/m2 will be given every 21 days to patients intravenously (i.v). over a 3-hour period via a central venous catheter (referred to as a "central line") which is a tube (ie, catheter) placed into a large vein that is used to administer medications. Dexamethasone 4 mg will be given orally (p.o.) the day before trabectedin and dexamethasone 20 mg will be given i.v. 30 minutes before trabectedin. Dexamethasone 4 mg p.o. will be given for 2 days following trabectedin administration.

Interventions

  • Drug: Trabectedin
    • Trabectedin 1.3 mg/m2 administered intravenously every 21 days.
  • Drug: Dexamethasone
    • Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose

Arms, Groups and Cohorts

  • Experimental: Trabectedin
    • Trabectedin 1.3 mg/m2 administered intravenously every 21 days. Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose.

Clinical Trial Outcome Measures

Primary Measures

  • Number of patients with objective response
    • Time Frame: Up to approximately 3 years

Secondary Measures

  • Overall survival (OS)
    • Time Frame: Up to approximately 3 years
  • The number of patients with adverse events
    • Time Frame: Up to approximately 3 years
  • Time to progression (TTP)
    • Time Frame: Up to approximately 3 years
  • Progression free survival (PFS),
    • Time Frame: Up to approximately 3 years

Participating in This Clinical Trial

Inclusion Criteria

  • Diagnosis of advanced or metastatic endometrial carcinoma – Progressive disease after 1 cytotoxic chemotherapy regimen given for advanced/metastatic disease – At least one measureable tumor lesion – Adequate bone marrow, hepatic and renal function – Performance status ECOG 0 or 1 Exclusion Criteria:

  • Prior exposure to trabectedin – Known hypersensitivity to dexamethasone or to any of the components of trabectedin – Less than 4 weeks since last radiation therapy or since last dose of hormonal therapy, biological therapy, therapy with any investigational agent, or chemotherapy – History of another neoplastic disease unless in remission for more than 5 years – Known metastases (spread) of cancer to the central nervous system or other serious illness as specified in the protocol – Current pregnancy, lactation, or childbearing potential without adequate method of contraception.

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
  • Collaborator
    • PharmaMar
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial, Study Director, Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.